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Locus
aGvHD
Risk #A #P HR Range p Value Range DSS Range
DSS
Mean
A* Low 11 389 0.64-1.57 0.2-0.8 1.04-5.66 2.62
High 4 214 1.78-3.45 \0.001-0.003 1.04-4.3 2.39
B* Low 4 200 1.28-1.48 0.118-0.538 1.74-2.81 2.53
High 2 30 3-3.34 \0.001-0.015 1.06-1.06 1.06
Cw* Low 18 578 0.46-2.88 0.057-0.899 1.52-23.9 15.1
High 17 600 1.67-6.22 0.001-0.043 1.52-23.86 15.97
DRB1* Low 25 729 0.47-2.25 0.079-0.985 1.3-13.33 4.91
High 2 76 2.13-3.19 \0.001-0.003 4.02-10.41 7.22
DQB1* Low 24 900 0.57-1.58 0.062-0.98 0.24-20.61 10.37
High 3 114 1.75-2.81 0.002-0.017 1.38-20.61 13.74
Oral Presentations S173combinations are 13.88 and 15.33, respectively. The following table
summarizes DSS means and ranges for high and low risk combina-
tions.
(Table 1) #A: # of allele combinations analyzed by Histocheck
#P: # of donor/patient pairs that have all the analyzed combina-
tions
HR: Hazard Ratios of developing severe aGvHD
P values: for the corresponding estimated hazard risk
Conclusion: Our analysis demonstrates that means and ranges of
DSS were interchangeable among high and low risk allele combina-
tions within loci A, B, and Cw. In loci DRB1 and DQB1 DSS means
were higher in the high risk combinations but the ranges remain
overlapping. This analysis does not support selecting donors for
HSCT recipients on the basis of low HistoCheck scores.IMMUNE RECONSTITUTION50
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Adoptive immunotherapy with peripheral blood (PB)-derived
CMV/Ad/EBV-specific CTL generated from seropositive donors ef-
fectively prevents viral disease after Peripheral Blood StemCell Trans-
plant (PBSCT),but this optionhasnotbeen feasiblewhen thedonorT-
cells are naive. PBSCT fromCMV-seronegative (CMVneg) donors to
CMV-seropositive (CMVpos) recipients produces a high incidence of
CMV infection since donor T-cells are naı¨ve to this virus. Umbilical
cord blood (CB) is an important source of stem cells for allotransplant
patients lacking human leukocyte antigen (HLA)-matched donors. T-
cells inCBgrafts are, however, also virus-naı¨ve, leading tohigher infec-
tions rates with CMV, EBV, adenovirus (Ad) and other viruses. Irre-
spective of whether the naive T-cells are sourced from CB or
CMVneg PB, CTL generation for clinical use from these donors has
been unsuccessful. We have now overcome this problem and can rou-
tinely generate CMV, Ad and EBV specific CTL fromCB and CMV-
specific CTLs from seronegative PB for clinical use. We used an
Ad5f35CMVpp65 vector to transduceCBor PBderived dendritic cells
and stimulated virus-specific CTL in the presence of IL-7, IL-12 and
IL-15.Thiswas followed by 2 stimulationswith autologous EBV-lym-
phoblastoid cell lines (LCL) transduced with the same vector. CB-de-
rived CTL were predominantly CD8+ (mean 87%;range 81-94) and
had significant cytotoxicity against CMVpp65, Adhexon/penton and
LCL targets. In addition, we generated CMVpp65, Adhexon/penton
and LCL-specific responses from the PB of 4 CMVneg adult donors,
which produced a mean of 92 (range 50-126), 163 (range 69-293),
and 62 (range 37-86) SFC to CMVpp65 respectively. Neither CB
nor CMVneg-derived CTL responded to irrelevant peptides. Of
note, thevirus-specificT-cells expanded fromCBandCMVnegdonorsderivedonly fromT-cellswithanaivephenotype (CD45RA+/CCR7+).
Moreover, both CB and CMVneg-derived CTL recognized ‘‘uncon-
ventional’’ CMVpp65 epitopes, as identified by overlapping pp65 pep-
tide pools and confirmed by IFN-g ELISPOT as well as multimer
analysis. In HLA-A2+ subjects, naive-derived CTL did not recognize
conventional HLA-A2 associated CMV pp65 epitopes such as NLV,
suggesting an inherent differencebetweennaı¨ve andmemoryT-cell re-
sponses to CMV. In summary, virus-specific responses T-cell re-
sponses can be obtained even from CB and virus-naive adult donors
andmayallowpreventionand treatmentof viraldisease in the recipients
of these allografts.
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DENDRITIC CELL FACILITATE THYMIC RECOVERY AND ENHANCE IM-
MUNE RECONSTITUTION AFTER HEMATOPOIETIC STEM CELL TRANS-
PLANT
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After hematopoietic stem cell transplantation (HSCT), the first
committed cells to engraft in the thymus are dendritic cells (DCs).
The role of thymic DCs in T cell production by ensuring efficient
tolerance and selection has been well demonstrated, however the
role of thymic DCs in facilitating donor engraftment has not been
investigated. Here we show addition of ex-vivo generated DCs
accelerates thymic engraftment as well as enhance T cell recovery
after HSCT. Control group received 103 lin-sca-1+c-kit+ (LSK)
(CD45.2) hematopoietic stem cell progenitors while the DCs group
received 103 LSK (CD45.2) cells along with 103 ex-vivo generated
DCs. DCs were generated using bone marrow from GFP+ CD57/
Bl mice (CD45.1/GFP+) and cultured for 7 days with GMCSF. On
the day of HSCT, C57/BL (CD45.1) recipients received lethal radi-
ation at 1000 cGy. At 4 and 7 days after HSCT, thymuses of theDCs
group had GFP+ CD11c+ cells present in the medullary region con-
firmed by immunohistochemistry and contained 1.8 and 4.2- fold,
respectively, higher number of thymocytes compared to control
group (p\0.05). Furthermore, thymuses of the DCs group showed
a 3.2 and 7.4-fold, respectively, higher number of thymoctyes
derived from donor LSK (CD45.2) cells compared to the control
group (p\0.05 and p\0.007). Two and four weeks after HSCT,
peripheral blood of DCs group contained at least 2.6 and 4.8-fold,
respectively, higher numbers of CD3+ cells derived from donor
LSK (CD45.2) cells compared to the control group (p\0.05).
Here, we demonstrate that ex-vivo generatedDCs efficientlymigrate
and home to the thymic medulla and hasten thymic recovery as dem-
onstrated by the higher number of total thymoctyes. Furthermore,
DCs facilitate thymic engraftment as shown by increase number of
donor thymoctyes. Lastly, recipients of DCs have earlier generation
of de-novo donor derived CD3+ T cells in the peripheral blood. By
using the GFP+ (CD45.1) cells along with donor LSK (CD45.2),
we were able to confirm that the facilitation of early thymic recovery
was due to the increased engraftment of the donor cells rather than
autologous recovery of the host. Thus, this study suggests that
DCs committed prior to thymic entry maintains the ability to
home to the medullary region and facilitate thymoctye recover and
hasten immune reconstitution after HSCT.52
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B cells have been demonstrated to present antigen to T cells in
vivo. CD40-activation dramatically improves antigen presentation
by normal and malignant B cells and has therefore been studied as
an approach to generate autologous ‘‘non-artificial’’ antigen present-
ing cells for active immunotherapy. Furthermore, CD40-B cells have
recently been shown to expand tumorantigen and viral specific CTL
